DiaMedica Therapeutics Inc. - Common Stock — Quarterly Financial Statistics (NASDAQ:DMAC) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -7.15 M-7.6 M-6.55 M-7.76 M-9.08 M -31 M Cash from investing activities 6.62 M8.96 M-25.77 M8 M-2.11 M -10.93 M Cash from financing activities 91 K161 K31.53 M12.09 M417 K 44.2 M Free cash flow -7.15 M-7.6 M-6.55 M-7.76 M-9.08 M -31 M

News

Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings - DiaMedica Therapeutics (NASDAQ:DMAC)

DiaMedica receives Health Canada clearance for preeclampsia study

Cantor Fitzgerald reiterates Overweight rating on DiaMedica stock

DiaMedica to conduct additional study for preeclampsia treatment

Cisco, Flutter, Manulife and more set to report earnings Wednesday

DiaMedica Therapeutics stock initiated with Buy rating at TD Cowen

Tracking Leon Cooperman’s ~$3B Omega Advisors Portfolio – Q2 2025 Update

DiaMedica Therapeutics, Inc. (DMAC) is a Great Momentum Stock: Should You Buy?

After Golden Cross, DiaMedica Therapeutics, Inc. (DMAC)'s Technical Outlook is Bright

Wall Street Analysts Believe DiaMedica Therapeutics (DMAC) Could Rally 100.81%: Here's is How to Trade

What Makes DiaMedica Therapeutics, Inc. (DMAC) a Strong Momentum Stock: Buy Now?

Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect?